167 related articles for article (PubMed ID: 20953648)
41. Bioisosteric Design Identifies Inhibitors of
Kamsri B; Pakamwong B; Thongdee P; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Sangswan J; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Leanpolchareanchai J; Goudar KE; Spencer J; Mulholland AJ; Pungpo P
J Chem Inf Model; 2023 May; 63(9):2707-2718. PubMed ID: 37074047
[TBL] [Abstract][Full Text] [Related]
42. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
43. Gyrase ATPase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues.
Jeankumar VU; Renuka J; Kotagiri S; Saxena S; Kakan SS; Sridevi JP; Yellanki S; Kulkarni P; Yogeeswari P; Sriram D
ChemMedChem; 2014 Aug; 9(8):1850-9. PubMed ID: 24962352
[TBL] [Abstract][Full Text] [Related]
44. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Hameed P S; Patil V; Solapure S; Sharma U; Madhavapeddi P; Raichurkar A; Chinnapattu M; Manjrekar P; Shanbhag G; Puttur J; Shinde V; Menasinakai S; Rudrapatana S; Achar V; Awasthy D; Nandishaiah R; Humnabadkar V; Ghosh A; Narayan C; Ramya VK; Kaur P; Sharma S; Werngren J; Hoffner S; Panduga V; Kumar CN; Reddy J; Kumar K N M; Ganguly S; Bharath S; Bheemarao U; Mukherjee K; Arora U; Gaonkar S; Coulson M; Waterson D; Sambandamurthy VK; de Sousa SM
J Med Chem; 2014 Jun; 57(11):4889-905. PubMed ID: 24809953
[TBL] [Abstract][Full Text] [Related]
45. Predictive models for nucleoside bisubstrate analogs as inhibitors of siderophore biosynthesis in Mycobacterium tuberculosis: pharmacophore mapping and chemometric QSAR study.
Tawari NR; Degani MS
Mol Divers; 2011 May; 15(2):435-44. PubMed ID: 20306296
[TBL] [Abstract][Full Text] [Related]
46. Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
Jeankumar VU; Reshma RS; Vats R; Janupally R; Saxena S; Yogeeswari P; Sriram D
Eur J Med Chem; 2016 Oct; 122():216-231. PubMed ID: 27371925
[TBL] [Abstract][Full Text] [Related]
47. ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines.
Saxena AK; Alam M
Curr Top Med Chem; 2020; 20(29):2723-2734. PubMed ID: 32885753
[TBL] [Abstract][Full Text] [Related]
48. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
Jeankumar VU; Renuka J; Santosh P; Soni V; Sridevi JP; Suryadevara P; Yogeeswari P; Sriram D
Eur J Med Chem; 2013; 70():143-53. PubMed ID: 24148991
[TBL] [Abstract][Full Text] [Related]
49. Pharmacophore assessment through 3-D QSAR: evaluation of the predictive ability on new derivatives by the application on a series of antitubercular agents.
Friggeri L; Ballante F; Ragno R; Musmuca I; De Vita D; Manetti F; Biava M; Scipione L; Di Santo R; Costi R; Feroci M; Tortorella S
J Chem Inf Model; 2013 Jun; 53(6):1463-74. PubMed ID: 23617317
[TBL] [Abstract][Full Text] [Related]
50. Structural insights of PA-824 derivatives: ligand-based 3D-QSAR study and design of novel PA824 derivatives as anti-tubercular agents.
Inturi B; Pujar GV; Purohit MN
J Recept Signal Transduct Res; 2015; 35(5):468-78. PubMed ID: 26053507
[TBL] [Abstract][Full Text] [Related]
51. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
[TBL] [Abstract][Full Text] [Related]
52. Pharmacophore generation, atom-based 3D-QSAR and molecular dynamics simulation analyses of pyridine-3-carboxamide-6-yl-urea analogues as potential gyrase B inhibitors.
Azam MA; Thathan J
SAR QSAR Environ Res; 2017 Apr; 28(4):275-296. PubMed ID: 28399673
[TBL] [Abstract][Full Text] [Related]
53. New molecular scaffolds for the design of Mycobacterium tuberculosis type II dehydroquinase inhibitors identified using ligand and receptor based virtual screening.
Kumar A; Siddiqi MI; Miertus S
J Mol Model; 2010 Apr; 16(4):693-712. PubMed ID: 19816720
[TBL] [Abstract][Full Text] [Related]
54. Discovery of 1,2,3-triazole based quinoxaline-1,4-di-N-oxide derivatives as potential anti-tubercular agents.
Srinivasarao S; Nandikolla A; Suresh A; Ewa AK; Głogowska A; Ghosh B; Kumar BK; Murugesan S; Pulya S; Aggarwal H; Sekhar KVGC
Bioorg Chem; 2020 Jul; 100():103955. PubMed ID: 32464405
[TBL] [Abstract][Full Text] [Related]
55. Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis.
Blower TR; Williamson BH; Kerns RJ; Berger JM
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):1706-13. PubMed ID: 26792525
[TBL] [Abstract][Full Text] [Related]
56. 3D-QSAR and molecular modeling studies on 2,3-dideoxy hexenopyranosid-4-uloses as anti-tubercular agents targeting alpha-mannosidase.
Shah P; Saquib M; Sharma S; Husain I; Sharma SK; Singh V; Srivastava R; Shaw AK; Siddiqi MI
Bioorg Chem; 2015 Apr; 59():91-6. PubMed ID: 25727263
[TBL] [Abstract][Full Text] [Related]
57. Recent advances in QSAR-based identification and design of anti-tubercular agents.
Nidhi ; Siddiqi MI
Curr Pharm Des; 2014; 20(27):4418-26. PubMed ID: 24245761
[TBL] [Abstract][Full Text] [Related]
58. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.
Matrat S; Veziris N; Mayer C; Jarlier V; Truffot-Pernot C; Camuset J; Bouvet E; Cambau E; Aubry A
Antimicrob Agents Chemother; 2006 Dec; 50(12):4170-3. PubMed ID: 17015625
[TBL] [Abstract][Full Text] [Related]
59. Identification of new DNA gyrase inhibitors based on bioactive compounds from streptomyces: structure-based virtual screening and molecular dynamics simulations approaches.
Kalhor H; Sadeghi S; Marashiyan M; Kalhor R; Aghaei Gharehbolagh S; Akbari Eidgahi MR; Rahimi H
J Biomol Struct Dyn; 2020 Feb; 38(3):791-806. PubMed ID: 30916622
[TBL] [Abstract][Full Text] [Related]
60. Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis.
Kashyap A; Singh PK; Silakari O
Tuberculosis (Edinb); 2018 Dec; 113():43-54. PubMed ID: 30514513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
